about
Phase 0 clinical trials in oncology new drug development.Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patientDesigning phase 0 cancer clinical trials.Early-phase development of cancer prevention agents: challenges and opportunitiesPhase 0 clinical studies in oncology.PARP inhibitors: polypharmacology versus selective inhibition.Role of Phase 0 trials in drug development.
P2860
Q34941964-AA94128B-C122-4FE3-9653-3265A8A2823FQ36732058-3729FD4A-6307-4707-8DF5-51C751184859Q36732115-B6FD5B38-B1D7-43B8-9FFD-6248D07B50B2Q36853927-42DBC058-8519-43DE-B7FD-E810360BE764Q37358487-79D1821C-5E46-4981-8642-9D7DBB4758E6Q38100299-761F0B39-099B-4629-85A1-ABCC17F3D91CQ39934032-73AC4D29-9701-44A9-AE6E-5C9FA12F475F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase 0 trials: an industry perspective.
@en
Phase 0 trials: an industry perspective.
@nl
type
label
Phase 0 trials: an industry perspective.
@en
Phase 0 trials: an industry perspective.
@nl
prefLabel
Phase 0 trials: an industry perspective.
@en
Phase 0 trials: an industry perspective.
@nl
P2093
P1476
Phase 0 trials: an industry perspective.
@en
P2093
Gary Gordon
Helen Eliopoulos
Rita Tiehen
Robert Carr
Terri Leahy
Vincent Giranda
P304
P356
10.1158/1078-0432.CCR-07-4586
P407
P577
2008-06-01T00:00:00Z